NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization694.4 mln
Float16.41 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
33.00
Transformational upside
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-11.70
Negative
Dividend Yield
0.00%
No dividend
Business Description
AgomAb Therapeutics, founded in 2017 and based in Antwerp, Belgium, is working to create new treatments for chronic inflammatory and fibrotic diseases where patients currently have few effective options. Its two most advanced drugs ? Ontunisertib, taken by mouth for fibrostenosing Crohn's disease, and AGMB-447, an inhaled therapy for idiopathic pulmonary fibrosis ? are both in early-stage clinical trials and work by blocking a protein linked to scarring and tissue damage. The company is also developing AGMB-101, an antibody designed to reduce fibrosis and support tissue repair, which has shown promising results in early laboratory studies.
